185 related articles for article (PubMed ID: 29477894)
1. Locomotor differences in mice expressing wild-type human α-synuclein.
Giraldo G; Brooks M; Giasson BI; Janus C
Neurobiol Aging; 2018 May; 65():140-148. PubMed ID: 29477894
[TBL] [Abstract][Full Text] [Related]
2. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
[TBL] [Abstract][Full Text] [Related]
3. Behavioural and dopaminergic changes in double mutated human A30P*A53T alpha-synuclein transgenic mouse model of Parkinson´s disease.
Kilpeläinen T; Julku UH; Svarcbahs R; Myöhänen TT
Sci Rep; 2019 Nov; 9(1):17382. PubMed ID: 31758049
[TBL] [Abstract][Full Text] [Related]
4. Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice.
Rabl R; Breitschaedel C; Flunkert S; Duller S; Amschl D; Neddens J; Niederkofler V; Rockenstein E; Masliah E; Roemer H; Hutter-Paier B
BMC Neurosci; 2017 Jan; 18(1):22. PubMed ID: 28143405
[TBL] [Abstract][Full Text] [Related]
5. Alpha-Synuclein transgenic mice, h-α-SynL62, display α-Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease.
Frahm S; Melis V; Horsley D; Rickard JE; Riedel G; Fadda P; Scherma M; Harrington CR; Wischik CM; Theuring F; Schwab K
Behav Brain Res; 2018 Feb; 339():153-168. PubMed ID: 29180135
[TBL] [Abstract][Full Text] [Related]
6. Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation.
Fishbein I; Kuo YM; Giasson BI; Nussbaum RL
Brain; 2014 Dec; 137(Pt 12):3235-47. PubMed ID: 25351739
[TBL] [Abstract][Full Text] [Related]
7. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
[TBL] [Abstract][Full Text] [Related]
8. Wild-type and mutant alpha-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD.
Miller RM; Kiser GL; Kaysser-Kranich T; Casaceli C; Colla E; Lee MK; Palaniappan C; Federoff HJ
Exp Neurol; 2007 Mar; 204(1):421-32. PubMed ID: 17254569
[TBL] [Abstract][Full Text] [Related]
9. Dopamine receptor agonists reverse behavioral abnormalities of alpha-synuclein transgenic mouse, a new model of Parkinson's disease.
Wakamatsu M; Iwata S; Funakoshi T; Yoshimoto M
J Neurosci Res; 2008 Feb; 86(3):640-6. PubMed ID: 17896793
[TBL] [Abstract][Full Text] [Related]
10. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice.
Richfield EK; Thiruchelvam MJ; Cory-Slechta DA; Wuertzer C; Gainetdinov RR; Caron MG; Di Monte DA; Federoff HJ
Exp Neurol; 2002 May; 175(1):35-48. PubMed ID: 12009758
[TBL] [Abstract][Full Text] [Related]
11. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death.
Martin LJ; Pan Y; Price AC; Sterling W; Copeland NG; Jenkins NA; Price DL; Lee MK
J Neurosci; 2006 Jan; 26(1):41-50. PubMed ID: 16399671
[TBL] [Abstract][Full Text] [Related]
12. Genomic DNA levels of mutant alpha-synuclein correlate with non-motor symptoms in an A53T Parkinson's disease mouse model.
Wang W; Song N; Jia F; Tang T; Bao W; Zuo C; Xie J; Jiang H
Neurochem Int; 2018 Mar; 114():71-79. PubMed ID: 29355568
[TBL] [Abstract][Full Text] [Related]
13. Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by α-synuclein overexpression.
Bourdenx M; Dovero S; Engeln M; Bido S; Bastide MF; Dutheil N; Vollenweider I; Baud L; Piron C; Grouthier V; Boraud T; Porras G; Li Q; Baekelandt V; Scheller D; Michel A; Fernagut PO; Georges F; Courtine G; Bezard E; Dehay B
Acta Neuropathol Commun; 2015 Jul; 3():46. PubMed ID: 26205255
[TBL] [Abstract][Full Text] [Related]
14. Comparison of motor performance, brain biochemistry and histology of two A30P α-synuclein transgenic mouse strains.
Piltonen M; Savolainen M; Patrikainen S; Baekelandt V; Myöhänen TT; Männistö PT
Neuroscience; 2013 Feb; 231():157-68. PubMed ID: 23219665
[TBL] [Abstract][Full Text] [Related]
15. Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression.
McLean JR; Hallett PJ; Cooper O; Stanley M; Isacson O
Mol Cell Neurosci; 2012 Feb; 49(2):230-9. PubMed ID: 22155155
[TBL] [Abstract][Full Text] [Related]
16. Brain infusion of α-synuclein oligomers induces motor and non-motor Parkinson's disease-like symptoms in mice.
Fortuna JTS; Gralle M; Beckman D; Neves FS; Diniz LP; Frost PS; Barros-Aragão F; Santos LE; Gonçalves RA; Romão L; Zamberlan DC; Soares FAA; Braga C; Foguel D; Gomes FCA; De Felice FG; Ferreira ST; Clarke JR; Figueiredo CP
Behav Brain Res; 2017 Aug; 333():150-160. PubMed ID: 28668282
[TBL] [Abstract][Full Text] [Related]
17. A novel α-synuclein-GFP mouse model displays progressive motor impairment, olfactory dysfunction and accumulation of α-synuclein-GFP.
Hansen C; Björklund T; Petit GH; Lundblad M; Murmu RP; Brundin P; Li JY
Neurobiol Dis; 2013 Aug; 56():145-55. PubMed ID: 23643841
[TBL] [Abstract][Full Text] [Related]
18. Exacerbated synucleinopathy in mice expressing A53T SNCA on a Snca null background.
Cabin DE; Gispert-Sanchez S; Murphy D; Auburger G; Myers RR; Nussbaum RL
Neurobiol Aging; 2005 Jan; 26(1):25-35. PubMed ID: 15585343
[TBL] [Abstract][Full Text] [Related]
19. Behavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson's disease.
Paumier KL; Sukoff Rizzo SJ; Berger Z; Chen Y; Gonzales C; Kaftan E; Li L; Lotarski S; Monaghan M; Shen W; Stolyar P; Vasilyev D; Zaleska M; D Hirst W; Dunlop J
PLoS One; 2013; 8(8):e70274. PubMed ID: 23936403
[TBL] [Abstract][Full Text] [Related]
20. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
